Phthalides

Worldwide Phthalic Anhydride Derivatives Industry to 2026 - Construction Sector to Dominate the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Chemicals, Plastics, Manufacturing, Commodity chemicals, Building materials, Materials, Dielectrics, Phthalic anhydride, Phthalides, Plasticizer, Plastic, Goods economics)

In recent years, the country's building sector has experienced huge investments.\nFurthermore, in Japan, in 2019, a sudden rise in residential construction and projects related to the Tokyo Olympics 2020 prompted the growth of the construction industry during 2019.

Key Points: 
  • In recent years, the country's building sector has experienced huge investments.\nFurthermore, in Japan, in 2019, a sudden rise in residential construction and projects related to the Tokyo Olympics 2020 prompted the growth of the construction industry during 2019.
  • However, with the outbreak of corona virus, the Tokyo Olympics is further postponed to 2021.\nIn addition, China is the world's biggest consumer of plastics.
  • With the growing packaging and industrial industries in the country, demand for plastics is projected to increase.
  • Because of these factors, demand for plasticizers is expected to increase in China, which, in turn, is expected to increase demand for phthalic anhydride used in plasticizers.\nHence, all such market trends are expected to drive the demand for phthalic anhydride derivatives market in the region during the forecast period.\n"

RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil

Retrieved on: 
Wednesday, April 7, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Chemical compounds, Immunosuppressants, Morpholines, Mycophenolic acid, Phenols, Phthalides, Pegloticase, Organic compounds, KRYSTEXXA, Horizon

Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in Arthritis & Rheumatology [ doi.org/10.1002/art.41731 ].

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in Arthritis & Rheumatology [ doi.org/10.1002/art.41731 ].
  • The safety and efficacy of KRYSTEXXA co-prescribed with mycophenolate mofetil has not been established by any health authorities.
  • During the trial, patients continued to receive either mycophenolate mofetil (1g) twice daily or placebo with KRYSTEXXA for 12 weeks.
  • Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout a Phase II Double Blind Placebo Controlled Randomized Trial.

Technavio's Phthalic Anhydride Market Report Identifies BASF SE, Exxon Mobil Corp., and IG Petrochemicals Ltd. as Key Vendors

Retrieved on: 
Wednesday, November 11, 2020
Other Natural Resources, Chemicals, Plastics, Oil, Gas, Manufacturing, Natural Resources, Energy, Other Manufacturing, Phthalic anhydrides, Phthalides, Phthalic anhydride, Health, Impact of the COVID-19 pandemic, COVID-19 pandemic, Articles, Infectious diseases

The report offers a detailed analysis of the impact of COVID-19 pandemic on the phthalic anhydride market in optimistic, probable, and pessimistic forecast scenarios.

Key Points: 
  • The report offers a detailed analysis of the impact of COVID-19 pandemic on the phthalic anhydride market in optimistic, probable, and pessimistic forecast scenarios.
  • View the full release here: https://www.businesswire.com/news/home/20201110005930/en/
    Technavio has announced its latest market research report titled Global Phthalic Anhydride Market 2020-2024 (Graphic: Business Wire)
    Enterprises will go through Response, Recovery, and Renew phases.
  • Download a Free Sample Report on COVID-19
    The phthalic anhydride market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
  • Get report snapshot here to get detailed market share analysis of market participants during COVID-19 lockdown: https://www.technavio.com/report/phthalic-anhydride-market-industry-anal...
    Phthalic anhydride market is segmented as below:

Phthalic Anhydride (PA): 2020 World Market Outlook and Forecast up to 2029 with COVID-19 Impact Estimation - ResearchAndMarkets.com

Retrieved on: 
Monday, September 28, 2020
Chemicals, Plastics, Manufacturing, Phthalic anhydrides, Phthalides, Phthalic anhydride

The "Phthalic Anhydride (PA): 2020 World Market Outlook and Forecast up to 2029 (with COVID-19 Impact Estimation)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Phthalic Anhydride (PA): 2020 World Market Outlook and Forecast up to 2029 (with COVID-19 Impact Estimation)" report has been added to ResearchAndMarkets.com's offering.
  • The report is an essential resource for a one looking for detailed information on the world phthalic anhydride market.
  • The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries.
  • In addition to the analytical part, the report provides a range of tables and figures which all together give a true insight into the national, regional and global markets for phthalic anhydride.

Insights on the Global Phthalic Anhydride Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats - Technavio

Retrieved on: 
Wednesday, September 2, 2020
Building Systems, Manufacturing, Commercial Building & Real Estate, Construction & Property, Chemicals, Plastics, Phthalic anhydrides, Phthalic anhydride, Phthalides, Compound annual growth rate, Academic disciplines

The phthalic anhydride market is expected to grow by USD 3.52 billion, accelerating at a CAGR of almost 7% during the forecast period.

Key Points: 
  • The phthalic anhydride market is expected to grow by USD 3.52 billion, accelerating at a CAGR of almost 7% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20200901006055/en/
    Technavio has announced its latest market research report titled Global Phthalic Anhydride Market 2020-2024 (Photo: Business Wire)
    The growth of the construction industry is one of the major factors propelling market growth.
  • However, the rising demand for bio-based chemicals will hamper market growth.
  • Therefore, the growth of the construction industry will have a positive impact on the growth of the global phthalic anhydride market during the forecast period.

Polynt-Reichhold Group Announces Further Details About Its Strategic Integration Initiative in the Americas

Retrieved on: 
Tuesday, July 14, 2020
Chemicals, Plastics, Oil, Gas, Transport, Manufacturing, Energy, Other Manufacturing, Other Transport, Chemistry, Physical sciences, Materials, Commodity chemicals, Composite materials, Phthalic anhydride, Phthalides, Maleic anhydride, Organic acid anhydride, Thermosetting polymer, Gelcoat

Rosario Valido, Group President and CEO commented: For Maleic Anhydride, we evaluated options for purchasing an existing plant, but this proved to not be feasible.

Key Points: 
  • Rosario Valido, Group President and CEO commented: For Maleic Anhydride, we evaluated options for purchasing an existing plant, but this proved to not be feasible.
  • Polynt-Reichhold is still evaluating its integration strategy for Phthalic Anhydride, the other chemistry included in the Strategic Integration Initiative.
  • Polynt-Reichhold Group is a global leader in composite materials, intermediate chemicals, coating resins, thermosetting composites, gel coats, and niche chemical specialties.
  • Polynt-Reichhold Group has over 3,300 employees in 37 manufacturing operations throughout North and South America, Europe and Asia.

Progressive-Fibrosing Interstitial Lung Disease (PF-ILD): Market Insights, Epidemiology and Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 27, 2020
Health, Other Health, Chemical compounds, Organic compounds, Medicine, Immunosuppressants, RTT, Morpholines, Mycophenolic acid, Phenols, Phthalides, Interstitial lung disease, Azathioprine, Nintedanib

The "Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Progressive-Fibrosing Interstitial Lung Disease (PF-ILD) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this research, the total prevalent population of Interstitial Lung Disease in seven major markets was 736,184 in 2017.
  • The current market size of PF-ILD is mainly attributed by corticosteroids, mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus, and cyclophosphamide.
  • The market size is expected to increase during the forecast period (2019-2028), due to potential therapies nintedanib (Ofev) and pirfenidone (Esbriet).

Study Reveals Possible Drug Treatment for Lupus Kidney Disease

Retrieved on: 
Wednesday, March 25, 2020
Medical specialties, Immunosuppressants, Medicine, Organ systems, Kidney diseases, RTT, Autoimmune diseases, Mycophenolic acid, Phthalides, Voclosporin, Systemic lupus erythematosus, Kidney disease

NEW YORK, March 25, 2020 /PRNewswire/ -- Today, the National Kidney Foundation (NKF) showcased a global study designed to understand the experimental immunosuppressant drug Voclosporin as a treatment for patients with lupus kidney disease.

Key Points: 
  • NEW YORK, March 25, 2020 /PRNewswire/ -- Today, the National Kidney Foundation (NKF) showcased a global study designed to understand the experimental immunosuppressant drug Voclosporin as a treatment for patients with lupus kidney disease.
  • Aurora is a global study designed tohelp us understand if adding voclosporin to mycophenolate mofetil (MMF) and steroids, common treatments for lupus kidney disease , will improve outcomes in patients with active lupus kidney disease.
  • "We know that achieving remission status in lupus kidney disease correlates with good long-term kidney survival and so the results of this study are very encouraging," added Dr. Gibson.
  • Based on the results of this study, Aurinia plans to file an application with the FDA for approval, which if approved, will open access to this medication to patients with lupus kidney disease.

Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared to Standard of Care Alone

Retrieved on: 
Saturday, November 9, 2019
Women, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Consumer, Clinical trials, Chemical compounds, Clinical research, Organic compounds, Health, Clinical trials, Medical statistics, Immunosuppressants, Mycophenolic acid, Phthalides, Clinical endpoint, Placebo, the NOBILITY Study, Lupus Nephritis, Gazyva, Genentech

The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care.

Key Points: 
  • The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care.
  • Gazyva additionally met key secondary efficacy endpoints showing improved overall renal response (complete or partial renal responses) and serologic markers of disease activity as compared to placebo.
  • The primary endpoint was the proportion of participants who achieved a protocol-defined complete renal response (CRR) at 52 weeks.
  • Key secondary endpoints included overall renal responses (complete or partial renal response) and serologic markers of disease activity, as compared to placebo.

Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients

Retrieved on: 
Wednesday, October 23, 2019
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Medical specialties, Medicine, Clinical medicine, Immunosuppressants, Macrolides, Mycophenolic acid, Phenols, Phthalides, Kidney transplantation, Tacrolimus, Organ transplantation

Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced the initiation of FREEDOM-1, the companys Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients.

Key Points: 
  • Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced the initiation of FREEDOM-1, the companys Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients.
  • FREEDOM-1 is an open-label, randomized clinical trial comparing FCR001 to a standard of care (tacrolimus and mycophenolate-based) regimen for LDKT recipients.
  • The trial has begun enrolling patients at its first clinical site, Northwestern Memorial Hospital, and additional trial sites will be announced in coming months.
  • The lead indication for FCR001 is to induce durable immune tolerance in living donor kidney transplant recipients.